| Prolonged infusion piperacillin-tazobactam decreases mortality and improves outcomes in severely ill patients: results of a systematic review and meta-analysis NJ Rhodes, J Liu, JN O’Donnell, JM Dulhunty, MH Abdul-Aziz, PY Berko, ... Critical care medicine 46 (2), 236-243, 2018 | 107 | 2018 |
| Evaluation of vancomycin exposures associated with elevations in novel urinary biomarkers of acute kidney injury in vancomycin-treated rats NJ Rhodes, WC Prozialeck, TP Lodise, N Venkatesan, JN O'Donnell, ... Antimicrobial agents and chemotherapy 60 (10), 5742-5751, 2016 | 63 | 2016 |
| Resistance trends and treatment options in gram-negative ventilator-associated pneumonia NJ Rhodes, CE Cruce, JN O’Donnell, RG Wunderink, AR Hauser Current infectious disease reports 20, 1-15, 2018 | 56 | 2018 |
| 24-hour pharmacokinetic relationships for vancomycin and novel urinary biomarkers of acute kidney injury JN O'Donnell, NJ Rhodes, TP Lodise, WC Prozialeck, CM Miglis, ... Antimicrobial agents and chemotherapy 61 (11), 10.1128/aac. 00416-17, 2017 | 49 | 2017 |
| Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection … TP Lodise, NM Smith, N O’Donnell, AE Eakin, PN Holden, ... Journal of Antimicrobial Chemotherapy 75 (9), 2622-2632, 2020 | 47 | 2020 |
| Optimal treatment of MSSA bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins MR Bidell, N Patel, JN O’Donnell Journal of Antimicrobial Chemotherapy 73 (10), 2643-2651, 2018 | 44 | 2018 |
| Comparative performance of urinary biomarkers for vancomycin-induced kidney injury according to timeline of injury GM Pais, SN Avedissian, JN O’Donnell, NJ Rhodes, TP Lodise, ... Antimicrobial agents and chemotherapy 63 (7), 10.1128/aac. 00079-19, 2019 | 42 | 2019 |
| Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model SN Avedissian, GM Pais, JN O’Donnell, TP Lodise, J Liu, WC Prozialeck, ... Journal of Antimicrobial Chemotherapy 74 (8), 2326-2334, 2019 | 40 | 2019 |
| Treatment of patients with serious infections due to carbapenem‐resistant Acinetobacter baumannii: How viable are the current options? JN O'Donnell, V Putra, TP Lodise Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 41 (9 …, 2021 | 37 | 2021 |
| Prevalence of a Cefazolin Inoculum Effect Associated with blaZ Gene Types among Methicillin-Susceptible Staphylococcus aureus Isolates from Four Major … SK Wang, A Gilchrist, A Loukitcheva, BJ Plotkin, IM Sigar, AE Gross, ... Antimicrobial Agents and Chemotherapy 62 (8), 10.1128/aac. 00382-18, 2018 | 34 | 2018 |
| Approach to the Treatment of Patients with Serious Multidrug‐Resistant Pseudomonas aeruginosa Infections JN O'Donnell, MR Bidell, TP Lodise Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 40 (9 …, 2020 | 32 | 2020 |
| New Perspectives on Antimicrobial Agents: Imipenem-Relebactam JN O’Donnell, TP Lodise Antimicrobial Agents and Chemotherapy 66 (7), e00256-22, 2022 | 24 | 2022 |
| Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens NJ Rhodes, ME Grove, PJ Kiel, JN O'Donnell, LK Whited, DT Rose, ... International journal of antimicrobial agents 50 (3), 482-486, 2017 | 24 | 2017 |
| Carbapenems vs. alternative β-lactams for the treatment of nosocomial pneumonia: A systematic review and meta-analysis JN O'Donnell, NJ Rhodes, J Lopez, R Jett, MH Scheetz International journal of antimicrobial agents 52 (4), 451-458, 2018 | 20 | 2018 |
| Visual and absorbance analyses of admixtures containing vancomycin and piperacillin–tazobactam at commonly used concentrations JN O’Donnell, N Venkatesan, M Manek, NJ Rhodes, MH Scheetz American Journal of Health-System Pharmacy 73 (4), 241-246, 2016 | 17 | 2016 |
| Outcomes and Risk Factors for Mortality among Patients Treated with Carbapenems for Klebsiella spp. Bacteremia LR Biehle, JM Cottreau, DJ Thompson, RL Filipek, JN O’Donnell, ... PloS one 10 (11), e0143845, 2015 | 17 | 2015 |
| Dose, duration, and animal sex predict vancomycin-associated acute kidney injury in preclinical studies JN O'Donnell, NJ Rhodes, CM Miglis, L Catovic, J Liu, C Cluff, G Pais, ... International journal of antimicrobial agents 51 (2), 239-243, 2018 | 16 | 2018 |
| The Pharmacodynamic-Toxicodynamic Relationship of AUC and Cmax in Vancomycin-Induced Kidney Injury in an Animal Model SN Avedissian, G Pais, J Liu, JN O’Donnell, TP Lodise, M Neely, ... Antimicrobial Agents and Chemotherapy 65 (3), 10.1128/aac. 01945-20, 2021 | 15 | 2021 |
| Tree-based models for predicting mortality in gram-negative bacteremia: avoid putting the CART before the horse NJ Rhodes, JN O'Donnell, BD Lizza, MM McLaughlin, JS Esterly, ... Antimicrobial agents and chemotherapy 60 (2), 838-844, 2016 | 15 | 2016 |
| High‐Performance Liquid Chromatography Method for Rich Pharmacokinetic Sampling Schemes in Translational Rat Toxicity Models With Vancomycin MD Joshi, JN O'Donnell, N Venkatesan, J Chang, H Nguyen, NJ Rhodes, ... Clinical and translational science 10 (6), 496-502, 2017 | 14 | 2017 |
